AI assistant
DBV Technologies S.A. — Director's Dealing 2025
Apr 7, 2025
33512_dirs_2025-04-07_a6eaf700-eaa1-484d-abdc-326860518181.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: DBV Technologies S.A. (DBVT)
CIK: 0001613780
Period of Report: 2025-03-27
Reporting Person: Bpifrance SA (10% Owner)
Reporting Person: Bpifrance Participations SA (10% Owner)
Reporting Person: CAISSE DES DEPOTS ET CONSIGNATIONS (10% Owner)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Ordinary Shares | 10672462 | Indirect |
| Ordinary Shares | 226133 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Warrants (right to buy) | $ | 2027-04-07 | Ordinary Shares (6556781) | Indirect |
Footnotes
F1: Bpifrance Participations S.A. ("Bpifrance Participations") directly owns the reported shares. Bpifrance Participations is a subsidiary owned at 99.99% by Bpifrance S.A. ("Bpifrance"). Bpifrance is jointly owned by Caisse des Depots et Consignations ("CDC") at 49.2% and EPIC Bpifrance ("EPIC") at 49.2%. CDC and EPIC jointly control Bpifrance.
F2: Innobio FPCI ("Innobio") directly owns the reported shares. Innobio is a fund managed by Bpifrance Investissement S.A.S. ("Bpifrance Investissement"), a subsidiary owned at 100% by Bpifrance Participations. Bpifrance Investissement may be deemed the beneficial owner of the reported shares, through its management of Innobio.
F3: The exercise of one warrant will give the right to subscribe to 1.75 ordinary shares at a price of (euro)1.5939 per warrant.